glp 1 agonist cardiovascular outcomes Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Glucagon-like peptide 1 receptor agonists:

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Find out more here.

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Obesity and Type 2 Diabetes has an increasing prevalence worldwide, presenting a major health challenge